Entity

Time filter

Source Type


King J.,Life Clinic
Journal of Psychoactive Drugs | Year: 2011

Best practices for Native Americans are rooted in culture. However, reclaiming best practices is a challenge given the genocidal policies that outlawed Native culture. Despite this challenge Native people have proven resilient in restoring culture. The Native American Health Center in Oakland, California, has made cultural interventions an option for an urban, intertribal and sometimes multiracial Native American population to create and maintain their health on a spiritual, emotional, mental and physical level. Nevertheless, sustaining these cultural options to maintain health continues to be a challenge. While the passage of the Mental Health Services Act (MHSA) in 2004 in California to transform treatment of mental and behavioral health "as we know it" would seem to create a gateway for cultural options, mainstream mental health has a hard time perceiving cultural interventions as a viable means to treat mental illness and maintain wellness. Frequently, the author has attended meetings of decisionmaking bodies that oversee how MHSA money is spent and someone will blurt out after someone has described an innovative cultural intervention "What does that have to do with mental illness?" The following article discusses how the clash of the two cultures, Native and mainstream, continues to be a challenge for sustained funding to implement culturally competent programs. © Taylor & Francis Group, LLC. Source


Matsueda K.,Life Clinic | Hongo M.,Tohoku University | Tack J.,Catholic University of Leuven | Saito Y.,Zeria Pharmaceutical Co. | Kato H.,Zeria Pharmaceutical Co.
Gut | Year: 2012

Objective: To determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial Methods: A multicentre, randomised, placebocontrolled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three mealrelated symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored. Results: 52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three mealrelated symptoms was 15.3% among patients receiving acotiamide compared with 9.0% in the placebo group (p=0.004). The significant benefit of acotiamide over placebo in OTE and elimination rate was maintained during the 4 week post-treatment follow-up. All other secondary efficacy end points, including quality of life, were significantly improved with 100 mg of acotiamide as compared with placebo. The number needed to treat was 6 for OTE and 16 for symptom elimination rate. The incidence of adverse events was similar between the acotiamide group and placebo group and no significant cardiovascular effects due to treatment were seen. Conclusions: Over 4 weeks, acotiamide significantly improved symptom severity and eliminated meal-related symptoms in patients with FD. Trial registration number: http://ClinicalTrials. gov number, NCT00761358. Source


Matsueda K.,Life Clinic | Hongo M.,Tohoku University | Ushijima S.,Astellas Pharma Inc. | Akiho H.,Astellas Pharma Inc.
Digestion | Year: 2011

Background: This long-term 48-week study of acotiamide was carried out to investigate the efficacy, safety and administration pattern in patients with functional dyspepsia (FD). Methods: This was a multicenter, open-label, single-arm, long-term phase III study in which patients with FD were given acotiamide, 100 mg t.i.d., for 48 weeks. The two major efficacy endpoints were global overall treatment efficacy (OTE) and the elimination rate of three cardinal symptoms (i.e. postprandial fullness, early satiation and upper abdominal bloating), which were evaluated weekly and daily by the patients, respectively. The long-term administration patterns were investigated by following the patients based on cessation and readministration criteria. Results: Efficacy was analyzed in 405 patients. The OTE improvement rate was 26.1% at week 1 and increased with time. It was 60.6% at week 8 and subsequently maintained. Similarly, the symptom elimination rate increased up to week 8. Many patients who met the cessation criterion achieved remission of FD symptoms after experiencing dose interruption and readministration. The incidence rate of adverse drug reactions was 11.5% and most of the adverse drug reactions were mild in severity except increased ALT in 1 patient. Conclusion: FD symptoms were controlled by intermittent administration of acotiamide even in patients with relapsing FD. Copyright © 2011 S. Karger AG, Basel. Source


Chompoo J.,Kagoshima University | Upadhyay A.,Kagoshima University | Kishimoto W.,University of Ryukyus | Makise T.,Life Clinic | Tawata S.,University of Ryukyus
Food Chemistry | Year: 2011

Advanced glycation end products (AGEs) are major factors responsible for the complication of diabetes. The present study was carried out to investigate the inhibitory activities on fructosamine adduct and α-dicarbonyl formations by hexane extracts of various parts of Alpinia zerumbet. Furthermore, we isolated two previously known compounds, namely 5,6-dehydrokawain (DK) and dihydro-5,6-dehydrokawain (DDK). 8(17),12-Labdadiene-15,16-dial (labdadiene) was isolated for the first time from the rhizome of A. zerumbet. The results showed that labdadiene (IC50 = 51.06 μg/mL) had similar activity to rutin and quercetin against fructosamine adduct. The inhibition of α-dicarbonyl compounds formation by labdadiene was significantly higher than that of DK and DDK. Our results indicate that labdadiene is a potent antiglycation agent which was found to inhibit AGEs formation in three different steps in the pathway. These data indicate that labdadiene could be used to prevent glycation-associated complications in diabetes. © 2011 Elsevier Ltd. All rights reserved. Source


Mlosek R.K.,Medical University of Warsaw | WoZniak W.,Medical University of Warsaw | Gruszecki L.,Life Clinic | Stapa R.Z.,Medical University of Warsaw
Phlebology | Year: 2014

Objective: Endovascular procedures are gaining more and more popularity as treatment of great saphenous vein (GSV) incompetence. The purpose of the present study was to assess the efficacy of steam GSV ablation. Methods: Steam ablation using the steam vein sclerosis system (CERMA, France) was performed in 20 patients with GSV incompetence. The efficacy of the procedure was evaluated using ultrasound and the following parameters were assessed: changes in lumen diameter, GSV wall thickness, reflux and presence/absence of blood flow. Results: The GSV steam ablation resulted in the obliteration of the vein lumen in all patients - reflux or blood flow were not observed in any subject. A significant decrease of GSV lumen diameter and an increase of GSV wall thickness were also observed in all subjects following the procedure. No postoperative complications were noted. The steam ablation technique was also positively assessed by the patients. Conclusions: Steam ablation is an endovascular surgical technique, which can become popular and widely used due to its efficacy and safety. It is also easy to use and patientfriendly. The research on its use should be continued. Source

Discover hidden collaborations